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Abstract: BACKGROUND Diabetes is the leading cause of CKD in the developed world. C-terminal
fragment of agrin (CAF) is a novel kidney function and injury biomarker. We investigated whether
serum CAF predicts progression of kidney disease in type 2 diabetics. METHODS Serum CAF levels
were measured in 71 elderly patients with diabetic nephropathy using a newly developed commercial
ELISA kit (Neurotune®). Estimated glomerular filtration rate (eGFR) and proteinuria in spot urine
were assessed at baseline and after 12 months follow up. The presence of end stage renal disease (ESRD)
was evaluated after 24 months follow-up. Correlation and logistic regression analyses were carried out to
explore the associations of serum CAF levels with GFR, proteinuria, GFR loss and incident ESRD. Renal
handling of CAF was tested in neurotrypsin-deficient mice injected with recombinant CAF. RESULTS
We found a strong association of serum CAF levels with eGFR and a direct association with proteinuria
both at baseline (r = 0.698, p<0.001 and r = 0. 287, p = 0.02) as well as after 12 months follow-up (r
= 0.677, p<0.001 and r = 0.449, p<0.001), respectively. Furthermore, in multivariate analysis, serum
CAF levels predicted eGFR decline at 12 months follow-up after adjusting for known risk factors (eGFR,
baseline proteinuria) [OR (95%CI) = 4.2 (1.2-14.5), p = 0.024]. In mice, injected CAF was detected
in endocytic vesicles of the proximal tubule. CONCLUSION Serum CAF levels reflect renal function
and are highly associated with eGFR and proteinuria at several time points. Serum CAF was able to
predict subsequent loss of renal function irrespective of baseline proteinuria in diabetic nephropathy. CAF
is likely removed from circulation by glomerular filtration and subsequent endocytosis in the proximal
tubule. These findings may open new possibilities for clinical trial design, since serum CAF levels may
be used as a selection tool to monitor kidney function in high-risk patients with diabetic nephropathy.
DOI: 10.1371/journal.pone.0143524
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BACKGROUND:  Diabetes is the leading cause of CKD in the industrialized world. C-terminal 26 
fragment of agrin (CAF) is a novel kidney function and injury biomarker. We investigated whether 27 
serum CAF predicts progression of kidney disease in type 2 diabetics. 28 
METHODS: Serum CAF levels were measured in 71 elderly patients with diabetic nephropathy 29 
using a newly developed commercial ELISA kit (Neurotune®). Estimated glomerular filtration rate 30 
(eGFR) and proteinuria in spot urine were assessed at baseline and after 12 months follow up. The 31 
presence of end stage renal disease (ESRD) was evaluated after 24 months. Correlation and logistic 32 
regression analyses were carried out to explore the associations of serum CAF levels with GFR, 33 
proteinuria, GFR loss and incident ESRD. Renal handling of CAF was tested in neurotrypsin-34 
deficient mice injected with recombinant CAF. 35 
RESULTS: We found a strong association of serum CAF levels with eGFR and a direct association 36 
with proteinuria both at baseline (r=0.698, p<0.001 and r=0. 287, p=0.02) as well as after 12 37 
months follow-up (r=0.677, p<0.001 and r=0.449, p<0.001), respectively. Furthermore, in 38 
multivariate analysis, serum CAF levels predicted eGFR decline at 12 months follow-up after 39 
adjusting for known risk factors (eGFR, baseline proteinuria) [OR(95%CI) 4.2(1.2-14.5), p=0.024]. In 40 
mice, injected CAF was detected in endocytic vesicles of the proximal tubule. 41 
CONCLUSION:  Serum CAF levels reflect renal function and are highly associated with eGFR and 42 
proteinuria at several time points. Serum CAF was able to predict subsequent loss of renal 43 
function irrespective of baseline proteinuria in diabetic nephropathy. CAF is likely removed from 44 
circulation by glomerular filtration and subsequent endocytosis in the proximal tubule. These 45 
findings may open new possibilities for clinical trial design, since serum CAF levels may be used as 46 
a selection tool to monitor kidney function in high risk patients with diabetic nephropathy. 47 
  48 
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Introduction  49 
Chronic kidney disease (CKD) represents a global public health problem affecting more than 1 in 50 
10 adults worldwide [1]. Diabetes is the leading cause of CKD in the industrialized world and 51 
people with both diabetes and chronic kidney disease have a greatly increased risk of all-cause 52 
mortality, cardiovascular mortality, and end-stage renal disease (ESRD) [2]. Although several 53 
factors have been identified to predict risk of developing progressive nephropathy in diabetic 54 
patient populations, none sufficiently predict the risk for individual patients [3].  55 
Currently the simultaneous evaluation of albuminuria and glomerular filtration rate (GFR) is 56 
recommended by the Kidney Disease Improving Global Outcomes (KDIGO) guidelines for the 57 
prediction of progression in diabetic nephropathy [4].  A growing body of evidence challenges the 58 
traditional conceptual model of the course of diabetic nephropathy [5,6], since it can present with 59 
a rapid decline of renal function and no overt albuminuria or progressive proteinuria [7,8,9,10]. 60 
Based upon these clinical observations, more reliable biomarkers are urgently needed in the clinic 61 
to predict renal outcome in patients with early stages of CKD in diabetic nephropathy [11]. 62 
Agrin is the major heparin sulfate proteoglycan in the glomerular basement membrane and a 63 
ubiquitous component of the extracellular matrix [12,13]. Neurotrypsin, a serine protease, cleaves 64 
agrin at two distinct molecular sites generating a 110 kDa fragment (CAF110) at the alpha site, 65 
whereas cleavage at the beta site produces the 22 kDa C-terminal fragment (CAF22) [14]. In 66 
human urine, CAF22 can be detected, suggesting renal clearance for this small fragment [15,16]. 67 
Furthermore, serum CAF22 (sCAF) as kidney function biomarker has only recently been explored in 68 
septic patients and in renal transplant recipients [17,18]. Both studies indicate that the sCAF 69 
concentration is associated and comparable to established parameters of renal function such as 70 
creatinine and cystatin C.   71 
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However, to date, there are no clinical studies which have investigated whether sCAF could serve 72 
as biomarker in clinical practice for diabetic nephropathy and no animal studies adressing the 73 
renal handling of sCAF. We hypothesize that rising sCAF levels may reflect progression of kidney 74 
damage and dysfunction. In this prospective study in a cohort of patients with diabetic 75 
nephropathy, we aimed to: 1) explore and validate the cross-sectional associations between sCAF 76 
and the currently used clinical markers of kidney damage and dysfunction; estimated glomerular 77 
filtration rate (eGFR) and proteinuria (protein to creatinine ratio [PCR]) and 2) examine the 78 
independent predictive performance of sCAF for renal function decline and ESRD. In addition we 79 




Study design and patient cohort 84 
The present study was designed as a prospective observational cohort study. Study subjects were 85 
recruited from the outpatient clinic of Department of Nephrology, University Hospital of 86 
Alexandroupoli, Greece.  Patients were recruited if they fulfilled the following inclusion criteria; (i) 87 
age > 18 years, (ii) ability to provide written, informed consent (iii) type 2 diabetes, defined as the 88 
use of oral glucose-lowering treatment , a fasting plasma glucose >7.0 mmol/l (126 mg/dl) or non-89 
fasting plasma glucose >11.1 mmol/l (>200 mg/dl). The presence of diabetic nephropathy was 90 
defined by microalbuminuria [albumin to creatinine ratio 3-30 mg/mmol (30-300mg/g)] or 91 
persistent albuminuria [(albumin: creatinine ratio >30 mg/mmol (>300mg/g)] in three consecutive 92 
measurements in sterile spot urine sample during a 6-month period, presence of diabetic 93 
retinopathy, and no clinical or laboratory evidence of kidney or urinary tract disease [19]. Subjects 94 
were considered to have diabetic retinopathy if they showed nonproliferative or proliferative 95 
5 
 
stages in fundoscopy through dilated pupils or had a history of retinal laser surgery 96 
(photocoagulation) for diabetic retinopathy. 97 
The main exclusion criteria were clinical or laboratory evidence of non-diabetic nephropathy such 98 
as active malignancy, infection, or auto-immune disease. The study was approved by the Ethics 99 
Committee of the Scientific Council of the University Hospital of Alexandroupoli, was in 100 
accordance with Helsinki Declaration of Human Rights and all subjects gave written informed 101 
consent. 102 
The diagnosis and staging of CKD was assessed based on the Clinical Practice Guidelines from the 103 
National Kidney Foundation–Kidney Disease Outcomes Quality Initiative [20]. GFR was estimated 104 
(eGFR) using the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI), which is 105 
more accurate and less biased than the MDRD Study equation, especially in patients with higher 106 
GFR, resulting in reduced misclassification of CKD [21]. The onset of ESRD was defined as the date 107 
of first dialysis or transplantation. 108 
 109 
Biochemical analysis 110 
After an overnight fasting of 8 h blood samples were drawn from a peripheral vein of the patients 111 
into vacutainer tubes without anticoagulant in order to obtain serum. Samples for fasting blood 112 
glucose levels, potassium, sodium, calcium, phosphate, protein, albumin, urea, creatinine and 113 
HbA1c were measured according to routine laboratory methods. Proteinuria was determined in 114 
spot urine by an automated biochemistry analyzer (Clinical Chemistry System ADVIA 2400, 115 
Siemens). Blood samples were immediately centrifuged at 4,000 rpm for 10 min at ambient 116 
temperature, and the extracted serum was aliquoted and stored at 253 K (-20 °C) until use. 117 
 118 
C-terminal agrin fragments (CAF) 119 
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CAF levels were measured using the NTtotalCAF ELISA kit from Neurotune AG 120 
(www.neurotune.com). This assay detects both the large C-terminal agrin fragment CAF110 121 
generated by alpha cleavage and the small C-terminal agrin fragment generated by beta cleavage 122 
(CAF22). The molecular ratio of both fragments is 1:5 (CAF110 vs CAF22). In brief, serum samples 123 
were diluted two-fold with sample incubation buffer and heated to 329 K (56°C) for 30 minutes. 124 
Samples were diluted 20 fold with dilution buffer. 100 μL of diluted sample was added to an ELISA 125 
plate precoated with a monoclonal catcher antibody raised against CAF. The plate was then 126 
incubated for 16 hours at room temperature. After rinsing 3 times with washing buffer, the 127 
monoclonal detector antibody was added for 30 minutes at room temperature. The plate was 128 
then washed as previously described [6]. Streptavidin- conjugated HRP was then added for 30 129 
minutes at room temperature. After washing, TMB substrate was added and developed for 30 130 
minutes. The reaction was then stopped with an acidic solution and the resulting absorbance was 131 
measured on an ELISA plate reader at 450 nm. The results were quantified using the calibration 132 
curve prepared independently on each individual plate. The lower detection limit was 40 pmol/L. 133 
Independent analysis revealed a mixed intra- and inter-assay %CV < 13 % for serum samples.  134 
 135 
Statistical analysis 136 
Variables were tested for normality using the Kolmogorov- Smirnov test. Comparisons between 137 
categorical variables were performed by the chi- square test or the Fisher’s exact test when 138 
appropriate. Differences in continuous variables between two groups were assessed using the 139 
Student’s t-test, the Mann-Whitney’s U-test or one-way ANOVA when appropriate. Pearson and 140 
Spearman correlation coefficients were calculated as appropriate between CAF or logarithmic 141 
transformed CAF (to achieve normal distribution), creatinine, GFR, proteinuria, age, BMI, HbA1c 142 
and duration of T2DM at baseline and at 12 months follow-up. Correlation analysis of decline of 143 
7 
 
renal function (ΔGFR) and progression to ESRD with various risk factors was also conducted to 144 
determine possible outcome predictors.  145 
Multiple logistic regression analysis was carried out to further explore the predictive role of serum 146 
CAF levels with GFR decline. The variables entered in the models were known risk factors 147 
associated with progression of kidney disease. For both outcomes a basic and an advanced model 148 
were used with the following variables:1) Basic model A: CAF, baseline GFR and baseline 149 
proteinuria and 2) Advanced model B: CAF, baseline GFR, baseline proteinuria, age and BMI. 150 
Variables retained in all final models were chosen according to clinical significance. A two-sided p 151 
value < 0.05 was considered significant. The IBM SPSS Statistics 20.0 statistical software package 152 
(SPSS Insc, Chicago, Illinois, USA) was used for all calculations.  153 
 154 
Animal experiments 155 
Experiments were performed in 8-10 weeks old male neurotrypsin knock-out mice (NT KO). The 156 
generation and genotyping of neurotrypsin KO mice has been previously described [22]. All animal 157 
experiments were conducted according to Swiss laws for the welfare of animals and were 158 
approved by the local Zurich Veterinary Authority (Kantonales Veterinäramt Zürich). The animals 159 
had free access to food and tap water. 160 
Mice were pretreated 60 min before experiments with an injection of leupeptin (5 mg/mouse, 161 
Sigma Aldrich, Buchs, Switzerland), an inhibitor of lysosomal degradation. Wildtype and 162 
neurotrypsin KO mice were anesthetized by i.p. injection of xylazin and ketamin and were injected 163 
with 100 ml of a mixture containing recombinant hCAF22 (100 ng/mouse, produced by 164 
Neurotune) dissolved in 0.9 % NaCl and FITC-labeled sinistrin (100 ng/ mouse). FITC-sinistrin is 165 
cleared from circulation exclusively by glomerular filtration and served as control for successful 166 
injection. Before injection of hCAF, the urinary bladder was completely emptied through a small 167 
8 
 
abdominal incision to allow collection of urine produced during the experimental period. Mice 168 
received also a bolus i.p. of 0.5 ml of 25 mM NaHCO3/150 mM NaCl to prevent dehydration and to 169 
promote diuresis. Mice were kept warm at 37 °C by placing animals on a heating tablet for the rest 170 
of the experiment. Twenty or 60 minutes after hCFA injections, mice perfused with PBS and PLP 171 
(see below) through the heart to obtain fixed kidneys for later immunohistochemistry and 172 
localization of recombinant  hCAF. 173 
 174 
Immunohistochemistry 175 
Mice were anesthetized with ketamine/xylazine (i.p.) and systemically perfused through the left 176 
ventricle with phosphate-buffered saline (PBS) to remove blood followed by paraformaldehyde-177 
lysine-periodate (PLP) fixative (50 ml/mouse) [23]. Kidneys were removed and fixed overnight at 178 
4°C by immersion in PLP. Kidneys were washed 3 times with PBS and 5 μm cryosections were cut 179 
after cryoprotection with 2.3 M sucrose in PBS for at least 12 h. Immunostaining was carried out 180 
as described previously [24]. Briefly, sections were shortly incubated in microwave with Tris-HC 181 
[pH 10], following 1% (wt/vol) SDS for 5 min for retrieval of antigenic sites, washed 3 times with 182 
PBS and incubated with PBS containing 1% bovine serum albumin for 15 min prior to the primary 183 
antibody. The primary antibodies were mouse monoclonal anti cleaved Agrin Abs (CAF; 14B7B8; 184 
1:1000) and (CAF; 12A11D11; 1:1000) (provided by Neurotune diluted in PBS and applied 185 
overnight at 4°C. Sections were then washed twice for 5 min with high NaCl PBS (PBS + 18 g 186 
NaCl/l), once with PBS, and incubated with dilutions of the secondary antibodies (donkey anti-187 
rabbit 594 (1:500), donkey anti-mouse 488 (1:200), donkey anti-mouse Alexa 594 (1:500), donkey 188 
anti-rabbit Alexa 488 (1:500)  (Molecular Probes, Oregon, USA) and from DAPI (1 mg/ml) (1:500) 189 
for 1 h at room temperature. Sections were again washed twice with high NaCl PBS and once with 190 
PBS before mounting with VectaMount (Vector Laboratories, Burlingame, CA). Sections were 191 
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viewed with a Zeiss LSM 410 confocal microscope or a Leica DFC490 charged-coupled device 192 
camera attached to a Leica DM 6000 fluorescence microscope (Leica, Wetzlar, Germany). Images 193 
were processed (overlays) using Adobe Photoshop. 194 
 195 
Results 196 
Study population 197 
A total of 71 consecutive patients with long standing (>10 years) diabetic nephropathy, were 198 
recruited from January 2010 to December 2014. A full medical history and physical examination 199 
was performed by a trained physician at baseline (time point 0; T0) and after 12 months (time 200 
point 1; T1). All patients were of Caucasian origin. Demographic, clinical and laboratory data of all 201 
enrolled patients at T0 and T1 as well as of groups of progressors (loss of GFR > 1ml/min/1.73m2) 202 
and non progressors (stable GFR) are given in Table 1.  203 
There was no significant difference in age, BMI and duration of T2DM across the categories of 204 
patients with and without GFR decline. Urea and phosphate concentrations were significantly 205 
different across groups and as expected, increased in the group of patients with decreased GFR 206 
(p=0.004, 0.03 respectively). There were significantly more males than females among GFR 207 
decliners compared with those with stable or increased GFR (62,5% vs 35,4%, p=0.024). sCAF 208 
levels showed a trend towards higher values in those with deterioration of renal function (p=0.09). 209 
 210 
Correlation analysis 211 
Correlation matrix analysis showed that values of creatinine and eGFR at both time-point 0 and 212 
time-point 1 were significantly associated with sCAF levels (p<0.001) (Table 2). sCAF concentration 213 
was also correlated with proteinuria at baseline and at T1 (p=0.02 and p<0.001, respectively) 214 
(Table 2). Furthermore, sCAF levels were strongly correlated with progression to ESRD (r=0.314, 215 
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p=0.008) (Table 2). At 24 months follow-up (time point 2; T2) 6 of the 71 patients progressed to 216 
ESRD (8.5%). Baseline sCAF levels were significantly elevated in those who reached ESRD 217 
compared to the group of patients that did not (p=0.009). sCAF also showed a significant 218 
association with the rapid increase of proteinuria (>500 mg/day) at T1 (r=0.340, p=0.004) (Table 219 
2). The baseline sCAF level was higher in those who presented a rapid increase of proteinuria than 220 
in patients with stable, decreased or mild increase (<500 mg/day) of proteinuria (p=0.005). A 221 
significant positive association was observed between rapid increase of proteinuria and 222 
progression to ESRD (x2, p=0.005). 223 
 224 
Logistic regression analysis 225 
Logistic regression models of the association of various renal outcomes (normal and rapid GFR 226 
loss) with baseline sCAF levels and other clinically significant regressors, assessed by 2 227 
complementary models: Basic model A (CAF, baseline GFR and baseline proteinuria) and advanced 228 
model B (CAF, baseline GFR, baseline proteinuria, age, BMI) are shown in Table 3. CAF was the 229 
only variable which was significantly associated with GFR loss (≥ 1 ml/min/1.73m2) in both model 230 
A [OR(95%CI) 4.2(1.2-14.5), p=0.024] and model B [OR(CI) 4.09(1.2-14.4), p=0.028].  231 
 232 
Animal experiments 233 
In order to test for the role of the kidney in determining serum CAF levels, we injected 234 
recombinant human CAF22 into neurotrypsin KO mice. These mice lack endogenous CAF22 due to 235 
the absence of the specific protease required for the cleavage of agrin [22]. In kidneys from NT KO 236 
mice injected with saline, no recombinant hCAF22 could be observed providing evidence for the 237 
specificity of the antibody. However, full length agrin was detected in the glomerulum and in the 238 
basement membrane of all tubules (Figure 1A). Twenty and sixty minutes after hCFA22 injections, 239 
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hCAF22 accumulated in subapical vesicles along the proximal tubule consistent with the 240 




Discussion  245 
The major findings in this prospective study of predominantly elderly patients with long-term 246 
diabetic nephropathy are that sCAF levels are strongly associated with eGFR and proteinuria. Of 247 
note these associations were preserved and evident in subsequent measurements for both 248 
parameters at T1. Higher baseline sCAF levels were significantly correlated with progression to 249 
ESRD and notably elevated in subjects with an overt increase of proteinuria at T1. Furthermore, 250 
sCAF levels predicted loss of renal function, as mirrored by eGFR decline at T1 even after adjusting 251 
for multiple well established risk factors, and in particular, for baseline GFR and proteinuria.  252 
Our results are consistent with previous studies that have reported associations between sCAF 253 
levels and renal function. Steubl et al. showed that sCAF was highly correlated with kidney 254 
function in a renal transplant cohort [18]. Additionally, Drey and colleagues demonstrated that 255 
sCAF levels are strongly associated and comparable to established renal function parameters 256 
(creatinine and cystatin C) in critical ill patients [17]. In the present study, serum levels of CAF at 257 
baseline were significantly higher in diabetics, which progressed to ESRD. Importantly, the 258 
association between sCAF levels and the different aspects of kidney dysfunction were also evident 259 
irrespective of proteinuria. Although sCAF levels reflect renal function and is highly associated with 260 
eGFR and proteinuria at several time points, it predicted loss of renal function also in the absence 261 
of proteinuria in diabetic nephropathy. sCAF seems to overcome a significant prognostic 262 
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restriction of proteinuria in a subset of patients with rapid decline of renal function and no 263 
progressive proteinuria, a finding that to our knowledge has not been reported before.  264 
Our animal experiments are consistent with the hypothesis that CAF22 is cleared from the 265 
circulation by glomerular filtration. Injected human recombinant hCAF22 accumulated in subapical 266 
vesicles along the proximal tubule. These vesicles likely represent endocytic vesicles containing 267 
low molecular weight proteins that escaped the glomerular filtration barrier. CAF22 has only 22 268 
kDa size and is expected to be filtered to a large extent similar to other proteins of this size [25]. 269 
The subapical localization of vesicles containing hCAF22 strongly suggests that hCAF22 is taken up 270 
from urine by endocytosis, possibly receptor-mediated endocytosis. It is unlikely that hCAF22 is 271 
secreted into urine by proximal tubules in quantitatively relevant amounts since we never 272 
detected hCAF22 positive vesicles close to the basolateral membrane.  Reabsorption of hCAF22 273 
along with other low molecular weight proteins will determine its urinary excretion. Thus, reduced 274 
glomerular filtration in kidney disease would increase serum CAF22 levels whereas a selective 275 
reduction in proximal tubular reabsorption may increase urinary CAF22 levels. While the exact 276 
mechanism of CAF production and trafficking in the kidney is currently under investigation, our 277 
findings further support the notion that CAF may reflect both structural (proteinuria) and 278 
functional (glomerular filtration rate) alterations. 279 
CKD has a major public impact worldwide, with a global prevalence of 10% and diabetic 280 
nephropathy is the primary reason of CKD [1,26,27]. sCAF may represent a promising biomarker of 281 
kidney damage and progression to ESRD in diabetic nephropathy. However, more studies with 282 
sufficient follow up are needed to evaluate the clinical value of sCAF measurements for: 1) the 283 
detection of kidney damage, 2) the prediction of GFR decline and 3) the development of ESRD. The 284 
correlation between sCAF levels and the progression of kidney dysfunction in other cohorts [28] as 285 
well as in the present study indicates that sCAF measurements may be of clinical importance. This 286 
13 
 
finding may open new possibilities for clinical trial design, since sCAF levels could be used as a 287 
selection tool for high-risk patients (individuals with CKD and in particular with diabetic 288 
nephropathy and no overt proteinuria at baseline) and for monitoring treatment effects in 289 
diabetic nephropathy.  290 
Limitations of the present study include the single center design, the short-term follow-up and 291 
unknown cross-relevance to other age and ethnic groups. While a multitude of relevant variables 292 
were adjusted in our multivariate analyses, as with all observational studies, it is possible that 293 
unmeasured confounders may have influenced our estimates and results. No conclusions 294 
regarding causality should be drawn from our prospective observational data. However, the strong 295 
associations with eGFR and proteinuria in diabetics are of interest because sCAF has been shown 296 
to be a prognostic marker of kidney dysfunction in other cohorts including patients with CKD and 297 
in critically ill patients with acute kidney injury [17,18]. 298 
Our findings suggest that sCAF, a novel kidney function and injury biomarker, is associated with 299 
subsequent renal function loss irrespective of proteinuria at baseline. The association we observed 300 
was strong and was not altered by adjusting for several risk factors. sCAF levels provide important 301 
information on the long-term outcome of patients with diabetic nephropathy, which exceed a 302 
simple reflection of glomerular filtration rate and proteinuria. sCAF measurements may have a 303 
substantial impact on clinical trial design as a selection tool since it holds the potential to identify 304 
individuals with the higher progression risk for diabetic nephropathy. Further studies are needed 305 
in order to replicate our results and to confirm sCAF as a monitoring tool for rapid disease 306 
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Table 1: Anthropometric, clinical, and biochemical characteristics of patients with TD2M and CKD 389 
with stable (or increased) and with decreased GFR at one year follow-up.  390 







Age (years) 70.9 (8.8) 71.8 (6.4) 70.2 (10.3) 0.79 
Gender (M/F) 36/35 11/20 25/15 0.024* 
BMI (kg/m2) 32.4 (5.9) 33.0 (5.9) 31.9 (6.0) 0.49 
Duration of T2DM (years) 17.4 (9.7) 16.5 (7.6) 18.1 (11.2) 0.83 
RAAS blockade (%) 49 (69) 25 (80.6) 24 (60) 0.06 
Urea (mg/dl) 13.1 (6.76) 10.5 (3.98) 15.1 (7.77) 0.004* 
Potassium (mEq/L) 4.8 (0.5) 4.7 (0.3) 4.9 (0.6) 0.34 
Sodium (mEq/L) 138.3 (3.0) 138.2 (3.0) 138.4 (3.0) 0.71 
Calcium (mmol/L) 2.35 (0.15) 2.38 (0.13) 2.33 (0.18) 0.35 
Phosphate (mmol/L) 1.23 (0.26) 1.16 (0.19) 1.29 (0.29) 0.03* 
Protein (g/L) 73 (6) 74 (07) 72 (6) 0.34 
Albumin (g/L) 43 (4) 44 (3) 42 (4) 0.06 
HbA1c (%) 8.6 (9.3) 7.5 (1.3) 9.5 (12.3) 0.88 
Crea T0 (mg/dl) 123.8 (53) 114.9 (35.4) 132.6 (61.9) 0.19 
Crea T1 (mg/dl) 123.8 (79.6) 106.1 (35.4) 150.3 (79.6) <0.001* 
eGFR T0 (ml/min/1.73 m2) 43 (27) 44 (23) 40.5 (30.5) 0.62 
eGFR T1 (ml/min/1.73 m2) 43 (27) 54 (24) 34 (23) <0.001* 
ΔGFR T0-T1 
(ml/min/1.73 m2) 
-2.0 (11) 5.0 (8) -6.0 (8) <0.001* 
PU T0 (mg/24h) 270 (600) 245 (430) 370 (705) 0.28 
PU T1 (mg/24h) 300 (770) 240 (490) 465 (985) 0.059 
ΔPU T0-T1 (mg/24h) 10 (270) 0 (200) 45 (390) 0.19 
ESRD (%) 6 (8.5) 0 (0) 6 (15) 0.024* 
Total CAF (pmol/L) 1091.4 (890.2) 993.4 (737.8) 1145.9 (1571.1) 0.09 
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Continuous variables are presented as mean (S.D.) or median (interquartile rangeIQR). P values of 391 
Mann-Whitney U or one-way ANOVA test for differences of variables among patients with stable 392 
or decreased eGFR at one year follow-up. * statistical significance at the 0.05 level (two-tailed) 393 
BMI, body mass index; HbA1c, glycosylated hemoglobin A1c; RAAS blockade, use of medicines 394 
affecting renin–angiotensin system; Crea T0, serum creatinine levels at timepoint 0 (baseline); 395 
Crea T1, serum creatinine levels at timepoint 1 (12 months); eGFR T0, estimated GFR assessed by 396 
the CKD-EPI formula at timepoint 0 (baseline); eGFR T1, estimated GFR assessed by the CKD-EPI 397 
formula at timepoint 1 (12 months); PU T0, Proteinuria assessed by protein to creatinine ratio at 398 
timepoint 0 (baseline); PU T1, Proteinuria assessed by protein to creatinine ratio at timepoint 1 399 
(12 months); ΔGFR T0-T1, Algebric difference between eGFR at timepoint 1 and eGFR at timepoint 400 
0; ΔPU T0-T1, Algebric difference between Proteinuria at timepoint 1 (12 months) and Proteinuria 401 
at timepoint 0 (baseline); ESRD, progression to end stage renal disease; Total-CAF, serum levels of 402 
C-terminal agrin fragment; Decreased GFR, patients with loss of eGFR ≥ 1 ml/min /1.73m2 during 403 
the 12 month follow-up.  404 
18 
 
TABLE 2: Correlation analysis of CAF levels with variables of laboratory and clinical significance and scatterplots of CAF with GFR and proteinuria. 
CAF levels (pmol/L) r p 
 
Age  ,032 0.79 
Body Mass Index  ,118 0.32 
HbA1c -,098 0.42 
Duration of T2DM  ,035 0.77 
Creatinine T0  ,705b <0.001* 
Creatinine T1  ,644b <0.001* 
Estimated GFR T0  -,698b <0.001* 
 
Estimated GFR T1  -,677b <0.001* 
Proteinuria T0  ,287a 0.02* 
Proteinuria T1  ,449b <0.001* 
End Stage Renal Disease ,314 0.008* 
Δ-Proteinuria T0-T1 ,340 0.004* 
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Values represent Spearman’s correlation coefficients.  
a Correlation is significant at the 0.05 level (2-tailed).  
HbA1c, glycosylated hemoglobin A1c; T0, Time point 0 (Baseline); T1, Time point 2 (12 months); Δ-
Proteinuria T0-T1, Increase of proteinuria (≥500mg/day) during the first year of follow-up.
20 
 












OR, odds ratio; CI, 95% confidence interval, *significance levels at 0.05 
BMI, body mass index; eGFR T0, estimated GFR assessed by the CKD-EPI formula at baseline; PU 
T0, Proteinuria assessed by protein to creatinine ratio at baseline; logCAF, serum CAF levels (log-
transformed). GFR, estimated glomerular filtration rate  
  
  GFR decline at 1 year ≥ 1 ml/min/1.73m2 
  OR  CI P 
Model 
A 
logCAF 4.18 1.2-14.5 0.024* 
eGFR T0 1.03 0.99-1.08 0.102 
PU T0 1.0002 0.99-1.0006 0.299 
Model 
B 
logCAF 4.09 1.16-14.4 0.028* 
eGFR T0 1.03 0.98-1.08 0.161 
PU T0 1.0002 0.99-1-0007 0.342 
Age 0.99 0.93-1.07 0.950 




Accumulation of recombinant hCAF22 in mouse proximal tubule. 
Mice were injected with saline or hCAF22 and all sections stained in parallel with the antibodies as 
indicated. A. Localization of full length agrin (red) and hCAF22 (green) in NT KO kidney injected 
with saline. B. Localization of full length agrin (red) and hCAF22 (green) in NT KO mouse kidney 20 
min after hCAF22 injections. C. Localizations of hCFA22 (green) and actin (red) in NT KO mouse 
kidney 20 min after hCAF22 injections. D. Localization of full length agrin (red) and hCAF22 (green) 
in NT KO mouse kidney 60 min after hCAF22 injections. E-F. Localizations of hCFA22 (green) and 
actin (red) in NT KO mouse kidney 60 min after hCAF22 injections. A- E Original magnifications 
between 400 - 630 x, for F original magnification 1000 x.  
